{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:00:24Z","timestamp":1790010024242,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T00:00:00Z","timestamp":1272326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11926-010-0104-3","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T08:01:02Z","timestamp":1272268862000},"page":"213-220","source":"Crossref","is-referenced-by-count":88,"title":["Drug-related Myopathies of Which the Clinician Should Be Aware"],"prefix":"10.1007","volume":"12","author":[{"given":"Ritu","family":"Valiyil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,27]]},"reference":[{"key":"104_CR1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp.2008.168294","volume":"80","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC: Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009, 80:832\u2013838.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"104_CR2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0b013e32830e2774","volume":"21","author":"T Klopstock","year":"2008","unstructured":"Klopstock T: Drug-induced myopathies. Curr Opin Neurol 2008, 21:590\u2013595.","journal-title":"Curr Opin Neurol"},{"key":"104_CR3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/WCO.0b013e32833045a0","volume":"22","author":"RW Kuncl","year":"2009","unstructured":"Kuncl RW: Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009, 22:506\u2013515.","journal-title":"Curr Opin Neurol"},{"key":"104_CR4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","volume":"83","author":"TA Jacobson","year":"2008","unstructured":"Jacobson TA: Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687\u2013700.","journal-title":"Mayo Clin Proc"},{"key":"104_CR5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"\u2022 Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858\u2013868. This is a nice comprehensive overview of statin myopathy to date.","journal-title":"Ann Intern Med"},{"key":"104_CR6","first-page":"6","volume":"9","author":"J Armitage","year":"2009","unstructured":"\u2022 MRC\/BHF Heart Protection Study Collaborative Group; Armitage J, Bowman L, Collins R, et al.: Effects of simvastatin 40\u00a0mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009, 9:6. This is one of the most comprehensive long-term, placebo-controlled trials undertaken to assess muscle and liver toxicity in patients at high risk for cardiovascular events.","journal-title":"BMC Clin Pharmacol"},{"key":"104_CR7","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:52C\u201360C.","journal-title":"Am J Cardiol"},{"key":"104_CR8","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","volume":"97","author":"H Bays","year":"2006","unstructured":"Bays H. Statin safety: an overview and assessment of the data\u20142005. Am J Cardiol 2006, 97:6C\u201326C.","journal-title":"Am J Cardiol"},{"key":"104_CR9","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","volume":"97","author":"PD Thompson","year":"2006","unstructured":"Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C\u201376C.","journal-title":"Am J Cardiol"},{"key":"104_CR10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/fampra\/cmp006","volume":"26","author":"D Mosshammer","year":"2009","unstructured":"Mosshammer D, Lorenz G, Meznaric S, et al.: Statin use and its association with musculoskeletal symptoms\u2014a cross-sectional study in primary care settings. Fam Pract 2009, 26:88\u201395.","journal-title":"Fam Pract"},{"key":"104_CR11","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2005.12.009","volume":"97","author":"TA Jacobson","year":"2006","unstructured":"Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97:44C\u201351C.","journal-title":"Am J Cardiol"},{"key":"104_CR12","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","volume":"97","author":"MH Davidson","year":"2006","unstructured":"Davidson MH, Clark JA, Glass LM, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97:32C\u201343C.","journal-title":"Am J Cardiol"},{"key":"104_CR13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"\u2022\u2022 SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al.: SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med 2008, 359:789\u2013799. This was a well-designed study with robust data for proof of principle of genetic susceptibility as a potential cause of statin myopathy.","journal-title":"N Engl J Med"},{"key":"104_CR14","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","volume":"54","author":"D Voora","year":"2009","unstructured":"\u2022 Voora D, Shah SH, Spasojevic I, et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609\u20131616. A sister study to that by the SEARCH Collaborative Group [13\u2022\u2022], this study eloquently expanded previous SNP association findings to suggest not only bona fide statin myopathy, but also that patients with myalgias with normal CK can also have a genetic predisposition that may be statin specific rather than a class effect.","journal-title":"J Am Coll Cardiol"},{"key":"104_CR15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","volume":"106","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024\u20131028.","journal-title":"Circulation"},{"key":"104_CR16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403\u2013414.","journal-title":"Cardiovasc Drugs Ther"},{"key":"104_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.21079","volume":"40","author":"A Supala-Berger","year":"2009","unstructured":"Supala-Berger A, Fine E, Heffner R, Young-McLain E: Hyaline inclusion myopathy: unmasked by statin therapy. Muscle Nerve 2009, 40:657\u2013661.","journal-title":"Muscle Nerve"},{"key":"104_CR18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","volume":"137","author":"PS Phillips","year":"2002","unstructured":"Phillips PS, Haas RH, Bannykh S, et al.; Scripps Mercy Clinical Research Center: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581\u2013585.","journal-title":"Ann Intern Med"},{"key":"104_CR19","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","volume":"181","author":"MG Mohaupt","year":"2009","unstructured":"Mohaupt MG, Karas RH, Babiychuk EB, et al.: Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11\u2013E18.","journal-title":"CMAJ"},{"key":"104_CR20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2008.09.023","volume":"399","author":"AH Wu","year":"2009","unstructured":"Wu AH, Smith A, Wians F: Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. Clin Chim Acta 2009, 399:109\u2013111.","journal-title":"Clin Chim Acta"},{"key":"104_CR21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","volume":"42","author":"JM Backes","year":"2008","unstructured":"\u2022 Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341\u2013346. This alternative dosing strategy offers an alternative dosing schedule for statin-intolerant patients.","journal-title":"Ann Pharmacother"},{"key":"104_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","volume":"103","author":"JF Ruisinger","year":"2009","unstructured":"\u2022 Ruisinger JF, Backes JM, Gibson CA, Moriarty PM: Once-a-week rosuvastatin (2.5 to 20\u00a0mg) in patients with a previous statin intolerance. Am J Cardiol 2009, 103:393\u2013394. Like that by Backes et al. [21\u2022], this study provided some data to suggest tolerability and efficacy for alternative statin dosing scheduled in statin-intolerant patients. This study noted a 17% reduction in total cholesterol, a 23% reduction in low-density lipoprotein cholesterol, a 12% reduction in triglycerides, and a 5% increase in high-density lipoprotein cholesterol (all P\u2009<\u20090.001) during a mean follow-up of 4\u2009\u00b1\u20092\u00a0months.","journal-title":"Am J Cardiol"},{"key":"104_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.metabol.2008.09.019","volume":"58","author":"CJ Glueck","year":"2009","unstructured":"Glueck CJ, Rawal B, Khan NA, et al.: Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009, 58:233\u2013238.","journal-title":"Metabolism"},{"key":"104_CR24","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","volume":"99","author":"JB Buse","year":"2007","unstructured":"ACCORD Study Group; Buse JB, Bigger JT, Byington RP, et al.: Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i\u201333i.","journal-title":"Am J Cardiol"},{"key":"104_CR25","doi-asserted-by":"crossref","first-page":"a2286","DOI":"10.1136\/bmj.a2286","volume":"337","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S, Lecky B: Statin induced myopathy. BMJ 2008, 337:a2286.","journal-title":"BMJ"},{"key":"104_CR26","doi-asserted-by":"crossref","first-page":"a2788","DOI":"10.1136\/bmj.a2788","volume":"337","author":"B Camilleri","year":"2008","unstructured":"Camilleri B: Statin induced myopathy. Use of statins with ciclosporin. BMJ 2008, 337:a2788.","journal-title":"BMJ"},{"key":"104_CR27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pds.1711","volume":"18","author":"C Rowan","year":"2009","unstructured":"Rowan C, Brinker AD, Nourjah P, et al.: Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009, 18:301\u2013309.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"104_CR28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"\u2022 Grable-Esposito P, Katzberg HD, Greenberg SA, et al.: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185\u2013190. This study demonstrated a robust association between a presumed necrotizing myopathy and statin exposure.","journal-title":"Muscle Nerve"},{"key":"104_CR29","doi-asserted-by":"crossref","unstructured":"\u2022 Christopher-Stine L, Casciola-Rosen L, Hong G, et al.: A novel autoantibody recognizing 200 and100\u00a0kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010 (in press). This study, along with that by Grable-Esposito et al. [28\u2022], shows that patients with statin exposure may go on to develop an immune-mediated myopathy\u2014often a necrotizing myopathy.","DOI":"10.1002\/art.27572"},{"key":"104_CR30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(01)00613-X","volume":"161","author":"LM Blanco-Colio","year":"2002","unstructured":"Blanco-Colio LM, Villa A, Ortego M, et al.: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17\u201326.","journal-title":"Atherosclerosis"},{"key":"104_CR31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mus.20603","volume":"34","author":"WW Campbell","year":"2006","unstructured":"Campbell WW: Statin myopathy: the iceberg or its tip? Muscle Nerve 2006, 34:387\u2013390.","journal-title":"Muscle Nerve"},{"key":"104_CR32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","volume":"150","author":"DJ Becker","year":"2009","unstructured":"Becker DJ, Gordon RY, Halbert SC, et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830\u2013839, W147\u2013W149.","journal-title":"Ann Intern Med"},{"key":"104_CR33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2125.2008.03224.x","volume":"66","author":"F Lapi","year":"2008","unstructured":"Lapi F, Gallo E, Bernasconi S, et al.: Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian surveillance system of natural health products. Br J Clin Pharmacol 2008, 66:572\u2013574.","journal-title":"Br J Clin Pharmacol"},{"key":"104_CR34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","volume":"105","author":"SC Halbert","year":"2010","unstructured":"Halbert SC, French B, Gordon RY, et al.: Tolerability of red yeast rice (2,400\u00a0mg twice daily) versus pravastatin (20\u00a0mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198\u2013204.","journal-title":"Am J Cardiol"},{"key":"104_CR35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1742-1241.2007.01592.x","volume":"62","author":"M Florentin","year":"2008","unstructured":"Florentin M, Liberopoulos EN, Elisaf MS: Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008, 62:88\u201396.","journal-title":"Int J Clin Pract"},{"key":"104_CR36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199004193221602","volume":"322","author":"MC Dalakas","year":"1990","unstructured":"Dalakas MC, Illa I, Pezeshkpour GH, et al.: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098\u20131105.","journal-title":"N Engl J Med"},{"key":"104_CR37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/brain\/98.3.473","volume":"98","author":"G Danta","year":"1975","unstructured":"Danta G, Hilton RC, Lynch PG: Chronic progressive external ophthalmoplegia. Brain 1975, 98:473\u2013492.","journal-title":"Brain"},{"key":"104_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1212\/WNL.0b013e3181aae814","volume":"73","author":"G Pfeffer","year":"2009","unstructured":"Pfeffer G, C\u00f4t\u00e9 HC, Montaner JS, et al.: Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology 2009, 73:71\u201372.","journal-title":"Neurology"},{"key":"104_CR39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","volume":"144","author":"AK Somani","year":"2008","unstructured":"Somani AK, Swick AR, Cooper KD, McCormick TS: Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008, 144:1341\u20131349.","journal-title":"Arch Dermatol"},{"key":"104_CR40","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","volume":"49","author":"JI Seok","year":"2009","unstructured":"Seok JI, Lee DK, Lee CH, et al.: Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49:2080\u20132086.","journal-title":"Hepatology"},{"key":"104_CR41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/ard.2004.023200","volume":"65","author":"E Casado","year":"2006","unstructured":"Casado E, Gratac\u00f3s J, Tolosa C, et al.: Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65:385\u2013390.","journal-title":"Ann Rheum Dis"},{"key":"104_CR42","first-page":"597","volume":"145","author":"AH Kalajian","year":"2009","unstructured":"Kalajian AH, Callen JP: Myopathy induced by antimalarial agents: the relevance of screening muscle enzyme levels. Arch Dermatol 2009, 145:597\u2013600.","journal-title":"Arch Dermatol"},{"key":"104_CR43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2000.109830","volume":"106","author":"RA Covar","year":"2000","unstructured":"Covar RA, Leung DY, McCormick D, et al.: Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000, 106:651\u2013659.","journal-title":"J Allergy Clin Immunol"},{"key":"104_CR44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0091-6749(85)90708-0","volume":"76","author":"SL Bowyer","year":"1985","unstructured":"Bowyer SL, LaMothe MP, Hollister JR: Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985, 76:234\u2013242.","journal-title":"J Allergy Clin Immunol"},{"key":"104_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2009.05.014","volume":"117","author":"AJ Dirks-Naylor","year":"2009","unstructured":"\u2022 Dirks-Naylor AJ, Griffiths CL: Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009, 117:1\u20137. This is an intriguing and novel concept to help elucidate the mechanism of glucocorticoid-related myopathy.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"104_CR46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/s10165-009-0181-1","volume":"19","author":"S Ochi","year":"2009","unstructured":"Ochi S, Taniguchi K, Nagashima M: Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod Rheumatol 2009, 19:443\u2013446.","journal-title":"Mod Rheumatol"},{"key":"104_CR47","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1345\/aph.1L025","volume":"42","author":"J Hinojosa","year":"2008","unstructured":"Hinojosa J, Borr\u00e1s-Blasco J, Maroto N, et al.: Severe myalgia associated with adalimumab treatment in a patient with Crohn\u2019s disease. Ann Pharmacother 2008, 42:1130\u20131133.","journal-title":"Ann Pharmacother"},{"key":"104_CR48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/RHU.0b013e318188bea7","volume":"15","author":"VK Shanmugam","year":"2009","unstructured":"Shanmugam VK, Matsumoto C, Pien E, et al.: Voriconazole-associated myositis. J Clin Rheumatol 2009, 15:350\u2013353.","journal-title":"J Clin Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0104-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0104-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0104-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T18:41:45Z","timestamp":1635273705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0104-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,27]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0104-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,27]]}}}